New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2014
34th Annual Global Healthcare Conference is being held in Boston on March 3-5 with webcasted company presentations to begin on March 5 at 8:00 am; not all company presentations may be webcasted. Webcast Link
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
March 18, 2015
08:07 EDTNKTRNektar weakness a buying opportunity, says Brean Capital
Brean Capital said it would use any weakness following Nektar's announcement of top line results for its breast cancer drug trial as a buying opportunity. The firm noted the trial missed its primary and secondary endpoints and has removed the revenue from their estimates, leading to a lowering of its price target to $17 from $20, but maintained its Buy rating on Nektar shares, citing its other opportunities.
07:02 EDTNKTRNektar price target lowered to $15 from $20 at Piper Jaffray
Subscribe for More Information
06:49 EDTNKTRNektar price target lowered to $17 from $19 at JPMorgan
Subscribe for More Information
March 17, 2015
19:42 EDTANTH, NKTROn The Fly: After Hours Movers
Subscribe for More Information
17:51 EDTNKTRNektar down 18% after NKTR-102 trial did not achieve statistical significance
17:40 EDTNKTRNektar to resume trading at 5:50 pm ET
Subscribe for More Information
16:19 EDTNKTRNektar says NKTR-102 trial did not achieve statistical significance
Nektar Therapeutics announced topline results from its Phase 3 BEACON study evaluating single-agent NKTR-102 in patients with advanced breast cancer. BEACON compared NKTR-102 to an active control arm comprised of a single chemotherapy agent of physician's choice in patients who were heavily pre-treated with a median of three prior therapies for metastatic disease. In a topline analysis of 852 patients from the trial, NKTR-102 provided a 2.1 month improvement in median overall survival over TPC. Based on a stratified log-rank analysis, the primary endpoint measuring the Hazard Ratio for survival in the NKTR-102 group compared to the active control arm was 0.87 with a p-value of 0.08, which did not achieve statistical significance. In a pre-specified subgroup of patients with a history of brain metastases, NKTR-102 showed an improvement of 5.2 months in median OS. The proportion of patients with brain metastases with 12-month survival was 44.4% in the NKTR-102 arm as compared to 19.4% in the control arm. In a pre-specified subgroup of patients with baseline liver metastases at study entry, NKTR-102 showed an improvement of 2.6 months in median OS. In these patients with baseline liver metastases, the proportion of patients with 12-month survival was 46.9% in the NKTR-102 arm as compared to 33.3% in the control arm. Secondary endpoints in the BEACON study included objective response rate and progression-free survival, which did not achieve statistical significance in the study. Nektar will continue to review and analyze the data from the BEACON study. Data from the BEACON study will be submitted for presentation at an upcoming medical meeting. "It is clear from our BEACON study that NKTR-102 has potential as an important anti-cancer agent when compared to the best available treatment options today for women with advanced breast cancer. Given the significant need for new drugs to treat patients with this devastating disease, we will be exploring potential paths forward for NKTR-102 in metastatic breast cancer with regulatory agencies," said Howard Robin, president and CEO of Nektar Therapeutics.
16:17 EDTNKTRNektar to explore potential regulatory pathways for NKTR-102 in U.S., Europe
Subscribe for More Information
16:16 EDTNKTRNektar says NKTR-102 trial did not achieve statistical significance
Subscribe for More Information
16:07 EDTANTHAnthera Pharmaceuticals files to sell common stock, no amount given
Subscribe for More Information
09:25 EDTSSHOn The Fly: Pre-market Movers
Subscribe for More Information
09:03 EDTBDXBecton Dickinson completes acquisition of CareFusion
Becton Dickinson (BDX) announced that it completed its acquisition of CareFusion (CFN) pursuant to the terms of its previously announced Agreement and Plan of Merger, dated October 5, 2014. Pursuant to the terms of the Merger Agreement, upon completion of the acquisition, CareFusion became a wholly-owned subsidiary of BD. Excluding transaction-related expenses relating to the closing, BD expects the acquisition to have an immaterial impact on the company's results of operations in the second fiscal quarter, which ends on March 31, 2015.
08:03 EDTABBVAbbVie to present data from 22 HUMIRA abstracts at AAD
Subscribe for More Information
06:31 EDTABBVStudies find Gilead's hepatitis C drugs cost effective, Reuters says
Subscribe for More Information
05:33 EDTSSHSunshine Heart provides update on Counter HF studies
Subscribe for More Information
05:30 EDTSSHSunshine Heart reports Q4 EPS (40c), consensus (40c)
Subscribe for More Information
March 16, 2015
15:04 EDTABBVPharmacyclics says committee recommends unblinding after primary endpoint met
Subscribe for More Information
08:45 EDTANTHAnthera Pharmaceuticals completes interim analysis from trial with Blisibimod
Anthera Pharmaceuticals, in collaboration with its partner Zenyaku Kogyo, announced that the BRIGHT-SC study of blisibimod in patients with IgA nephropathy should continue to completion as planned. This follows the successful completion of an interim futility analysis, conducted by an independent statistician, which evaluated several important biomarkers of renal disease in patients who had completed at least 8 weeks of treatment. As previously disclosed, following meetings with the European Medicines Agency, the Japanese PMDA, the US FDA, and our partner Zenyaku Kogyo, the company amended the BRIGHT-SC protocol prior to the interim analysis to reflect collective feedback. All agencies were receptive to the use of proteinuria as a surrogate endpoint with appropriate post-marketing studies.
08:22 EDTANTHAnthera Pharmaceuticals reports Q4 EPS (32c), consensus (33c)
08:14 EDTANTHAnthera Pharmaceuticals enters $10.3M purchase agreement
Anthera has filed a supplement for the sale of up to $10,300,000 in shares of our common stock to Lincoln Park Capital Fund, LLC, or Lincoln Park, under a Purchase Agreement entered into on March 12, 2015, or the Purchase Agreement.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use